GlobalData found that Oncology was the largest therapy area for clinical trials in...
June’s top news stories
Servier and Galapagos commenced the ROCCELLA Phase 2 clinical trial to evaluate the efficacy and safety of S201086/GLPG1972 to treat patients with knee osteoarthritis (OA); and Boehringer Ingelheim Pharmaceuticals and Eli Lilly and Company reported positive top-line results from the EASE trial programme. Drugdevelopment-technology.com wraps up the key news stories from June 2018.
Zepatier for the Treatment of Chronic Hepatitis C Genotype 1 and 4 Infection
Zepatier is a once-daily oral medicine comprising 50mg of non-structural protein 5A (NS5A) replication complex inhibitor elbasvir and 100mg of NS3/4A protease inhibitor grazoprevir.
Ocrevus (ocrelizumab) for the Treatment of Multiple Sclerosis
Developed by Genentech, Ocrevus (ocrelizumab) is indicated for the treatment of relapsing multiple sclerosis (MS) and primary progressive MS.
Laser Microdissection with PALM MicroBeam Technology
Its laser microdissection with PALM MicroBeam technology allows for contact-free and uncontaminated specimen collection from specific compartments of skin and hair follicles for use in next-generation sequencing analysis.
May’s top news stories
Abivax unveiled new data that may suggest its clinical candidate ABX464 could be a safe, functional cure for human immunodeficiency virus (HIV), as well as a method to treat inflammatory diseases; and Cancer Research UK and Experimental Cancer Medicine Centres (ECMC) Network joint venture (JV) Combinations Alliance started the SeluDex trial, a Phase I clinical study to evaluate selumetinib in combination with dexamethasone for treating leukaemia.
Parsabiv™ (etelcalcetide) for the Treatment of Secondary Hyperparathyroidism (SHPT)
Parsabiv™ (etelcalcetide) is an intravenous injectable calcimimetic agent developed by Amgen for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD) that were previously treated with haemodialysis.
Oncology: the ups and downs of enrollment in China
GlobalData found that Oncology was the largest therapy area for clinical trials in China. Infectious Disease was the second largest area, followed by Cardiovascular, Metabolic Disorders, and Central Nervous System.
AACR 2018: revisiting murine models to develop drug combos for KRAS-driven cancers
Treatment of KRAS-driven cancers is among one of the highest unmet needs in the oncology space.
Lack of CMO availability threatens cell and gene therapy development
With a lack of contract manufacturing organizations (CMOs) operating in the cell and gene therapies sphere, it appears to be heading towards major capacity crunches in both R&D and commercial manufacturing.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.